Artikel
Tolerability and safety of recombinant zoster vaccine in patients with inflammatory rheumatic musculoskeletal diseases – a prospective longitudinal study over 6 months
Suche in Medline nach
Autoren
-
Uta Kiltz
- Rheumazentrum Ruhrgebiet, Herne; Ruhr-Universität Bochum, Bochum
-
Xenofon Baraliakos
- Rheumazentrum Ruhrgebiet, Herne; Ruhr-Universität Bochum, Bochum
-
David Kiefer
- Rheumazentrum Ruhrgebiet, Herne; Ruhr-Universität Bochum, Bochum
-
Ioana Andreica
- Rheumazentrum Ruhrgebiet, Herne; Ruhr-Universität Bochum, Bochum
-
Benjamin Wilde
- University Hospital Essen, University of Duisburg-Essen, Department of Nephrology, Essen
-
Jürgen Braun
- Ruhr-Universität Bochum, Bochum
-
Stefania Reale
- Rheumazentrum Ruhrgebiet, Herne; Ruhr-Universität Bochum, Bochum
-
Gianna Intini
- Rheumazentrum Ruhrgebiet, Herne; Ruhr-Universität Bochum, Bochum
-
Hilal Kavruk
- Rheumazentrum Ruhrgebiet, Herne; Ruhr-Universität Bochum, Bochum
-
Dimitra Karagkiozidou
- Rheumazentrum Ruhrgebiet, Herne; Ruhr-Universität Bochum, Bochum
-
Barbara Guminski
- Rheumazentrum Ruhrgebiet, Herne; Ruhr-Universität Bochum, Bochum
-
Andreas Kribben
- University Hospital Essen, University of Duisburg-Essen, Department of Nephrology, Essen
| Veröffentlicht: | 30. August 2023 |
|---|
Gliederung
Text
Introduction: Herpes zoster (HZ) is common in the elderly with a lifetime risk of 25% [1]. The primary risk factors for HZ are advanced age and immunosuppression. The objective is to describe the safety of recombinant zoster vaccine in patients with inflammatory rheumatic and musculoskeletal diseases (RMD).
Methods: Adult patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and giant cell arteritis (GCA) were prospectively included. Data on demographics, vaccination, RMD diagnosis, disease activity, immunosuppressive treatments, flares, adverse events (AEs) and zoster breakthrough infections were collected at month 0, 2, 3 and 6. A flare was defined as change in ASDAS ≥0.9 for axSpA, change in DAS-28>1.2 for RA, or clinical signs for GCA and/or CRP ≥0.5 mg/dl and/or ≥30 mm. Descriptive analyses were performed.
Results: 50 patients were included of whom 18 (36.0%) had a history of HZ (table 1 [Tab. 1]). All patients received RZV at month 0, and 49 patients at month 2. Safety assessments were performed in 49, 48 and 36 patients in months 2, 3 and 6, respectively. A total of 62, 35, 11 AE in 38, 33, and 10 patients, respectively, were reported (figure 1 [Fig. 1]). Localized AE (n=69 (63.9%)) were far more common than generalized AE (n=28 (25.9%)). Pain at the site of injection in 46 (42.6%) patients was the most frequent AE followed by fatigue (12 (11.0%)), redness at the injection site in (9 (8.3%)), swelling at the injection site (7 (6.4%)) and fever (5 (4.6%)). Serious AEs were reported in 6 patients (2 RA, 4 GCA). None of them with causal relation to RZV. No patient reported an AE of special interest. Out of 6, 4 and 4 flares reported by patients at month 2, 3 and 6, respectively, no one fulfilled predefined flare criteria and were rated as mild to moderate. However, 3 patients (2 GCA, 1 RA) were hospitalized due to flares. No episodes of HZ occurred.
Conclusion: The majority of patients tolerated RZV well with only a few reports of flare and serious AEs. The majority of AEs occurred within a few days after vaccination. These findings are reassuring for rheumatologists and potential vaccine recipients and support confidence in RZV safety in patients with RMD.
References
- 1.
- Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004 Jan;4(1):26-33. DOI: 10.1016/s1473-3099(03)00857-0
